Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship
Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the pre...
Gespeichert in:
Veröffentlicht in: | European urology 2016-02, Vol.69 (2), p.276-283 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 283 |
---|---|
container_issue | 2 |
container_start_page | 276 |
container_title | European urology |
container_volume | 69 |
creator | Cai, Tommaso Verze, Paolo Brugnolli, Anna Tiscione, Daniele Luciani, Lorenzo Giuseppe Eccher, Cristina Lanzafame, Paolo Malossini, Gianni Wagenlehner, Florian M.E Mirone, Vincenzo Bjerklund Johansen, Truls E Pickard, Robert Bartoletti, Riccardo |
description | Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p < 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p < 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidel |
doi_str_mv | 10.1016/j.eururo.2015.05.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760875898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0302283815004121</els_id><sourcerecordid>1760875898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0EotvCP0DIRy5Zxsna8XJAWlWlrVQJpNKz5dhj1ksSB9sB7Zk_jsMWDlyQRvLXM-_Yr4eQVwzWDJh4e1jjHOcY1jUwvoYSDJ6QFZNtU7VcwFOyggbqqpaNPCPnKR0AoOHb5jk5qwUUCQYr8nNn9xhxNEhzoFdFb0I90l1KwXidfRhpcPQhhj58OdLr2Vvs_YiJloNPBd4fe22yN3Q3Zt_5UKbpXVnQ22EKMesx0_uME_Xjb2LwJobO637Z_aGjTXs_vSDPnO4TvnwcL8jDh6vPlzfV3cfr28vdXWU4E7kSHFzn6nrrNNN2w7Vs6m2nhW4t74RxrO1k6_jG2QJJLgQz3FjZdk6jEa1pLsibk-4Uw7cZU1aDTwb7Xo8Y5qRYK0C2XG5lQTcntFw3pYhOTdEPOh4VA7XYrw7qZL9a7FdQgkFJe_1YYe4GtH-T_vhdgPcnAMs7v3uMKhm_uG99RJOVDf5_Ff4VMOU_vNH9VzxiOoQ5jsVDxVSqFaj7pQWWDmAcYMNq1vwCKVSwRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760875898</pqid></control><display><type>article</type><title>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cai, Tommaso ; Verze, Paolo ; Brugnolli, Anna ; Tiscione, Daniele ; Luciani, Lorenzo Giuseppe ; Eccher, Cristina ; Lanzafame, Paolo ; Malossini, Gianni ; Wagenlehner, Florian M.E ; Mirone, Vincenzo ; Bjerklund Johansen, Truls E ; Pickard, Robert ; Bartoletti, Riccardo</creator><creatorcontrib>Cai, Tommaso ; Verze, Paolo ; Brugnolli, Anna ; Tiscione, Daniele ; Luciani, Lorenzo Giuseppe ; Eccher, Cristina ; Lanzafame, Paolo ; Malossini, Gianni ; Wagenlehner, Florian M.E ; Mirone, Vincenzo ; Bjerklund Johansen, Truls E ; Pickard, Robert ; Bartoletti, Riccardo</creatorcontrib><description>Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p < 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p < 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidelines reduced the rate of bacterial resistance, in particular against piperacillin/tazobactam, gentamicin, and ciprofloxacin, and reduced costs without increasing the risk of postoperative infection after urologic procedures. We recommend adherence to the guidelines as an important part of antibiotic stewardship programmes.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2015.05.010</identifier><identifier>PMID: 26001610</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - economics ; Anti-Bacterial Agents - therapeutic use ; Antibiotic Prophylaxis - standards ; Antimicrobial prophylaxis ; Ciprofloxacin - therapeutic use ; Cost saving ; Drug Resistance, Bacterial ; Escherichia coli - drug effects ; Europe ; Female ; Gentamicins - therapeutic use ; Guideline Adherence ; Guidelines ; Humans ; Klebsiella - drug effects ; Male ; Middle Aged ; Penicillanic Acid - analogs & derivatives ; Penicillanic Acid - therapeutic use ; Piperacillin - therapeutic use ; Piperacillin, Tazobactam Drug Combination ; Practice Guidelines as Topic ; Surgical urology ; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use ; Urinary tract infection ; Urologic Surgical Procedures - adverse effects ; Urologic Surgical Procedures - standards ; Urology ; Urology - standards</subject><ispartof>European urology, 2016-02, Vol.69 (2), p.276-283</ispartof><rights>European Association of Urology</rights><rights>2015 European Association of Urology</rights><rights>Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</citedby><cites>FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283815004121$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26001610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cai, Tommaso</creatorcontrib><creatorcontrib>Verze, Paolo</creatorcontrib><creatorcontrib>Brugnolli, Anna</creatorcontrib><creatorcontrib>Tiscione, Daniele</creatorcontrib><creatorcontrib>Luciani, Lorenzo Giuseppe</creatorcontrib><creatorcontrib>Eccher, Cristina</creatorcontrib><creatorcontrib>Lanzafame, Paolo</creatorcontrib><creatorcontrib>Malossini, Gianni</creatorcontrib><creatorcontrib>Wagenlehner, Florian M.E</creatorcontrib><creatorcontrib>Mirone, Vincenzo</creatorcontrib><creatorcontrib>Bjerklund Johansen, Truls E</creatorcontrib><creatorcontrib>Pickard, Robert</creatorcontrib><creatorcontrib>Bartoletti, Riccardo</creatorcontrib><title>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p < 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p < 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidelines reduced the rate of bacterial resistance, in particular against piperacillin/tazobactam, gentamicin, and ciprofloxacin, and reduced costs without increasing the risk of postoperative infection after urologic procedures. We recommend adherence to the guidelines as an important part of antibiotic stewardship programmes.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - economics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic Prophylaxis - standards</subject><subject>Antimicrobial prophylaxis</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Cost saving</subject><subject>Drug Resistance, Bacterial</subject><subject>Escherichia coli - drug effects</subject><subject>Europe</subject><subject>Female</subject><subject>Gentamicins - therapeutic use</subject><subject>Guideline Adherence</subject><subject>Guidelines</subject><subject>Humans</subject><subject>Klebsiella - drug effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Penicillanic Acid - analogs & derivatives</subject><subject>Penicillanic Acid - therapeutic use</subject><subject>Piperacillin - therapeutic use</subject><subject>Piperacillin, Tazobactam Drug Combination</subject><subject>Practice Guidelines as Topic</subject><subject>Surgical urology</subject><subject>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><subject>Urinary tract infection</subject><subject>Urologic Surgical Procedures - adverse effects</subject><subject>Urologic Surgical Procedures - standards</subject><subject>Urology</subject><subject>Urology - standards</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk1v1DAQhi0EotvCP0DIRy5Zxsna8XJAWlWlrVQJpNKz5dhj1ksSB9sB7Zk_jsMWDlyQRvLXM-_Yr4eQVwzWDJh4e1jjHOcY1jUwvoYSDJ6QFZNtU7VcwFOyggbqqpaNPCPnKR0AoOHb5jk5qwUUCQYr8nNn9xhxNEhzoFdFb0I90l1KwXidfRhpcPQhhj58OdLr2Vvs_YiJloNPBd4fe22yN3Q3Zt_5UKbpXVnQ22EKMesx0_uME_Xjb2LwJobO637Z_aGjTXs_vSDPnO4TvnwcL8jDh6vPlzfV3cfr28vdXWU4E7kSHFzn6nrrNNN2w7Vs6m2nhW4t74RxrO1k6_jG2QJJLgQz3FjZdk6jEa1pLsibk-4Uw7cZU1aDTwb7Xo8Y5qRYK0C2XG5lQTcntFw3pYhOTdEPOh4VA7XYrw7qZL9a7FdQgkFJe_1YYe4GtH-T_vhdgPcnAMs7v3uMKhm_uG99RJOVDf5_Ff4VMOU_vNH9VzxiOoQ5jsVDxVSqFaj7pQWWDmAcYMNq1vwCKVSwRw</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Cai, Tommaso</creator><creator>Verze, Paolo</creator><creator>Brugnolli, Anna</creator><creator>Tiscione, Daniele</creator><creator>Luciani, Lorenzo Giuseppe</creator><creator>Eccher, Cristina</creator><creator>Lanzafame, Paolo</creator><creator>Malossini, Gianni</creator><creator>Wagenlehner, Florian M.E</creator><creator>Mirone, Vincenzo</creator><creator>Bjerklund Johansen, Truls E</creator><creator>Pickard, Robert</creator><creator>Bartoletti, Riccardo</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</title><author>Cai, Tommaso ; Verze, Paolo ; Brugnolli, Anna ; Tiscione, Daniele ; Luciani, Lorenzo Giuseppe ; Eccher, Cristina ; Lanzafame, Paolo ; Malossini, Gianni ; Wagenlehner, Florian M.E ; Mirone, Vincenzo ; Bjerklund Johansen, Truls E ; Pickard, Robert ; Bartoletti, Riccardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-650fbf229fa1ad45a8329ba6a7d5b6cf17b87f54fdf2285661c5cd87bfaec67c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - economics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic Prophylaxis - standards</topic><topic>Antimicrobial prophylaxis</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Cost saving</topic><topic>Drug Resistance, Bacterial</topic><topic>Escherichia coli - drug effects</topic><topic>Europe</topic><topic>Female</topic><topic>Gentamicins - therapeutic use</topic><topic>Guideline Adherence</topic><topic>Guidelines</topic><topic>Humans</topic><topic>Klebsiella - drug effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Penicillanic Acid - analogs & derivatives</topic><topic>Penicillanic Acid - therapeutic use</topic><topic>Piperacillin - therapeutic use</topic><topic>Piperacillin, Tazobactam Drug Combination</topic><topic>Practice Guidelines as Topic</topic><topic>Surgical urology</topic><topic>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</topic><topic>Urinary tract infection</topic><topic>Urologic Surgical Procedures - adverse effects</topic><topic>Urologic Surgical Procedures - standards</topic><topic>Urology</topic><topic>Urology - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cai, Tommaso</creatorcontrib><creatorcontrib>Verze, Paolo</creatorcontrib><creatorcontrib>Brugnolli, Anna</creatorcontrib><creatorcontrib>Tiscione, Daniele</creatorcontrib><creatorcontrib>Luciani, Lorenzo Giuseppe</creatorcontrib><creatorcontrib>Eccher, Cristina</creatorcontrib><creatorcontrib>Lanzafame, Paolo</creatorcontrib><creatorcontrib>Malossini, Gianni</creatorcontrib><creatorcontrib>Wagenlehner, Florian M.E</creatorcontrib><creatorcontrib>Mirone, Vincenzo</creatorcontrib><creatorcontrib>Bjerklund Johansen, Truls E</creatorcontrib><creatorcontrib>Pickard, Robert</creatorcontrib><creatorcontrib>Bartoletti, Riccardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cai, Tommaso</au><au>Verze, Paolo</au><au>Brugnolli, Anna</au><au>Tiscione, Daniele</au><au>Luciani, Lorenzo Giuseppe</au><au>Eccher, Cristina</au><au>Lanzafame, Paolo</au><au>Malossini, Gianni</au><au>Wagenlehner, Florian M.E</au><au>Mirone, Vincenzo</au><au>Bjerklund Johansen, Truls E</au><au>Pickard, Robert</au><au>Bartoletti, Riccardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>69</volume><issue>2</issue><spage>276</spage><epage>283</epage><pages>276-283</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><abstract>Abstract Background The evolution of resistant pathogens is a worldwide health crisis and adherence to European Association of Urology (EAU) guidelines on antibiotic prophylaxis may be an important way to improve antibiotic stewardship and reduce patient harm and costs. Objective To evaluate the prevalence of antibiotic-resistant bacterial strains and health care costs during a period of adherence to EAU guidelines in a tertiary referral urologic institution. Design, setting, and participants A protocol for adherence to EAU guidelines for antibiotic prophylaxis for all urologic procedures was introduced in January 2011. Data for 3529 urologic procedures performed between January 2011 and December 2013 after protocol introduction were compared with data for 2619 procedures performed between January 2008 and December 2010 before protocol implementation. The prevalence of bacterial resistance and health care costs were compared between the two periods. Outcome measurements and statistical analysis The outcome measures were the proportion of resistant uropathogens and costs related to antibiotic consumption and symptomatic postoperative infection. We used χ2 and Fisher's exact tests to test the significance of differences. Results and limitations The proportion of patients with symptomatic postoperative infection did not differ (180/3529 [5.1%] vs 117/2619 [4.5%]; p = 0.27). A total of 342 isolates from all patients with symptomatic postoperative infections were analysed. The rate of resistance of Escherichia coli to piperacillin/tazobactam (9.1% vs 5.4%; p = 0.03), gentamicin (18.3% vs 11.2%; p = 0.02), and ciprofloxacin (32.3% vs 19.1%; p = 0.03) decreased significantly after protocol introduction. The defined daily dose (DDD) use of ciprofloxacin fell from 4.2 to 0.2 DDD per 100 patient-days after implementation ( p < 0.001). Antibiotic drug costs (€76 980 vs €36 700) and costs related to postoperative infections (€45 870 vs €29 560) decreased following introduction of the protocol ( p < 0.001). Conclusions Adherence to EAU guidelines on antibiotic prophylaxis reduced antibiotic usage without increasing post-operative infection rate and lowered the prevalence of resistant uropathogens. Patient summary We analysed the impact of adherence to European Association of Urology guidelines on antibiotic prophylaxis for all surgical urologic procedures on the prevalence of infections and resistant bacterial strains and on costs. We found that adherence to the guidelines reduced the rate of bacterial resistance, in particular against piperacillin/tazobactam, gentamicin, and ciprofloxacin, and reduced costs without increasing the risk of postoperative infection after urologic procedures. We recommend adherence to the guidelines as an important part of antibiotic stewardship programmes.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>26001610</pmid><doi>10.1016/j.eururo.2015.05.010</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0302-2838 |
ispartof | European urology, 2016-02, Vol.69 (2), p.276-283 |
issn | 0302-2838 1873-7560 |
language | eng |
recordid | cdi_proquest_miscellaneous_1760875898 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Aged Aged, 80 and over Anti-Bacterial Agents - economics Anti-Bacterial Agents - therapeutic use Antibiotic Prophylaxis - standards Antimicrobial prophylaxis Ciprofloxacin - therapeutic use Cost saving Drug Resistance, Bacterial Escherichia coli - drug effects Europe Female Gentamicins - therapeutic use Guideline Adherence Guidelines Humans Klebsiella - drug effects Male Middle Aged Penicillanic Acid - analogs & derivatives Penicillanic Acid - therapeutic use Piperacillin - therapeutic use Piperacillin, Tazobactam Drug Combination Practice Guidelines as Topic Surgical urology Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use Urinary tract infection Urologic Surgical Procedures - adverse effects Urologic Surgical Procedures - standards Urology Urology - standards |
title | Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A27%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20European%20Association%20of%20Urology%20Guidelines%20on%20Prophylactic%20Antibiotics:%20An%20Important%20Step%20in%20Antimicrobial%20Stewardship&rft.jtitle=European%20urology&rft.au=Cai,%20Tommaso&rft.date=2016-02-01&rft.volume=69&rft.issue=2&rft.spage=276&rft.epage=283&rft.pages=276-283&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2015.05.010&rft_dat=%3Cproquest_cross%3E1760875898%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760875898&rft_id=info:pmid/26001610&rft_els_id=1_s2_0_S0302283815004121&rfr_iscdi=true |